Entries by Thomas Gabrielczyk

INDUSTRIA BIOTEC 2023 with a broader perspective

"Solutions for an endangered planet" is what industrial biotechnology seeks and offers. Technical innovations based on nature’s toolbox are intended to help "biologise" industry – in other words, to adapt it to the natural cycles of our planet.

Pharma industry on expansion course

At the CPHI, the world’s largest pharmaceutical event, which attracted 40,405 visitors this year, it became evident that the COVID-19 pandemic has had an extremely positive impact on the (bio)pharmaceutical sector. A new CPHI annual survey shows how business will develop in the future. Particularly, the prospects for CDMOs and CROs are excellent.

Blow-Fill-Seal technology and vaccine delivery

Unit-dose?The SARS-CoV2 pandemic caused 6.3 million deaths and contaminated 545 million people across the world. In spite of the rapid development and approval of vaccines, the shortages of consumables like glass vials limited the distribution of prophylactic vaccines. Blow-Fill-Seal (BFS) is an alternative solution with advantages that could play an important role in vaccine distribution worldwide.

Amgen wins race of top `22 deals with $26bn for Horizon thx

According to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. This would be the largest acquisition in the company’s history.

Making a better cheese

The French company Standing Ovation uses precision fermentation to create the protein that gives cheese its unique properties. With his pitch, co-founder and CEO Frédéric P’ques took the prize at the start-up pitch of the Industria Biotech.

AGC Biologics doubles mammalian capacity

With a new expansion coming online in Copenhagen, AGC Biologics is offering more capacity in Europe for mammalian biologics projects using innovative single-use bioreactor technology. This is the latest in a string of new investments from the global CDMO to expand capacity and upgrade technology at its sites in Europe, Japan and the United States.

Unleashing the power of LNP encapsulation

The Covid-19 pandemic has changed perception of the value of ­rapid ­vaccine production, followed by multi-billion investments across the globe. While nanomedicines are receiving attention for enhancing stability and targeted activity of APIs, their broad availability ­currently suffers from the same production bottleneck as mRNA vaccines. Leon-nanodrugs, a pharma technology company, is developing a disruptive approach to unlock high-speed vaccine production.

LISAvienna’s 20th anniversary celebration was a blast

Vienna is one of Europe’s most dynamic innovation hubs in the life sciences. End of ­September, the life science community met to celebrate LISAvienna. For 20 years, LISAvienna has been acting as the cluster’s central point of contact. In close collaboration with Austria’s support and funding ecosystem, the platform accompanies and supports bioentrepreneurs through the ups and downs of their journey to transfer innovative business ideas into viable products and services.